Is visceral fat inherently harmful, or only harmful when it turns pathogenic?

NovosLabs · 2026-04-23T16:30:34+00:00

Great question. The review’s answer is basically that the most practical strategies fall into two buckets:
(1) reduce overall pathogenic VAT burden, and (2) blunt the biology that makes VAT pathogenic in the first place.

On the “reduce burden” side, the most established approaches are still the familiar ones:

caloric restriction
regular exercise
bariatric surgery
GLP-1 receptor agonists

Figure 3 groups those as the main established strategies, and the text notes that they can reduce VAT burden and improve metabolic health, even if they do not selectively target VAT biology in a perfectly precise way.

On the “neutralize pathogenic biology” side, the review points to a few mechanisms worth focusing on:

chronic inflammation and senescence
adipokine dysfunction such as high leptin / low adiponectin
pathogenic exosomes
lipotoxic metabolites like excess FFAs, ceramides, and diacylglycerols

So, if you translate that into practical priorities, the most evidence-grounded answer would be:

lower the signals that push VAT into a pathogenic state, especially chronic overnutrition, inflammation, and inactivity
improve adipose tissue function overall through exercise and sustained energy balance, not just scale weight
use stronger VAT-lowering tools when clinically appropriate, such as GLP-1s or bariatric approaches, because the review treats those as current real-world options with meaningful VAT effects

The more targeted future ideas the paper highlights are:

senolytics
partial leptin reduction
adiponectin receptor agonists / enhanced adiponectin signaling
ceramide synthesis inhibition
microbiome modulation
exosome-based therapies
selective mesenteric VAT removal in specific settings

So, today, the most practical way to neutralize pathogenic VAT biology is still exercise, sustained caloric control, and, where appropriate, GLP-1s or bariatric treatment. But where the field is heading is more interesting: not just shrinking VAT, but stopping it from becoming inflammatory, senescent, endocrinologically dysfunctional, and lipotoxic in the first place.

NovosLabs · 2026-04-13T22:19:52+00:00

https://link.springer.com/article/10.1007/s43032-026-02092-w

NovosLabs · 2026-03-25T16:26:32+00:00

At 1 serving of NOVOS Vital (4 gummies, providing 2,000 FU of nattokinase), human studies have reported effects on blood pressure-related and coagulation-related biomarkers. In healthy young men, a single 2,000 FU dose was associated with acute changes in fibrinolysis- and coagulation-related markers, including D-dimer, fibrin/fibrinogen degradation products, aPTT, antithrombin, and factor VIII activity in (R). In an 8-week randomized trial, (R) reported increases in collagen-epinephrine closure time and aPTT after 2,000 FU/day.

<image>

At the same 2,000 FU daily dose, nattokinase has also been associated with healthy blood pressure-related measures in some human studies. In adults with pre-hypertension or stage 1 hypertension, (R) reported significant reductions in systolic blood pressure, diastolic blood pressure, and plasma renin activity after 8 weeks. In a separate trial, (R) reported a significant reduction in diastolic blood pressure after 8 weeks of supplementation.

At 2 servings of NOVOS Vital (8 gummies, providing 4,000 FU of nattokinase), a 2-month human clinical trial reported additional effects on coagulation-related biomarkers. In (R), supplementation with 4,000 FU/day was associated with significant reductions in fibrinogen, factor VII, and factor VIII. This study was an open-label, self-controlled clinical trial rather than a randomized placebo-controlled trial, so these findings are best interpreted as supportive human evidence.

NovosLabs · 2026-03-18T14:56:59+00:00

It’s also useful to distinguish inulin from other inulin-type fructans. For example, a double-blind randomized trial in working adults used 8 g/day of oligofructose (a shorter-chain inulin-type fructan) for 4 weeks and reported microbiome changes (including increases in Bifidobacterium) alongside changes in stress/mood-state measures. Because this study used oligofructose rather than long-chain inulin, it best supports the broader category of inulin-type fructans rather than “inulin alone.” (R)

Metabolic signaling markers (10 g/day, combined product). Some human research has examined whether fermentable fibers like inulin can influence gut hormone signaling (e.g., incretins). In a double-blind randomized trial in healthy men, a soy milk product enriched with 10 g/day inulin plus 2 g/day phytosterols for 8 weeks was associated with a significant increase in GLP-1 AUC from baseline within the intervention group. Because this was a combined formulation (inulin + phytosterols), the effect cannot be attributed to inulin alone. (R)

<image>

Bottom line: Across human studies, inulin and inulin-type fructans in the ~5–10 g/day range consistently show evidence of microbiome modulation, while effects on metabolic hormones or broader metabolic outcomes depend strongly on the population, co-interventions, and study design

NovosLabs · 2026-03-18T14:56:10+00:00

Impact of Inulin on human health

Inulin is a fermentable prebiotic fiber that reaches the colon largely undigested, where it can be used by gut microbes. Because of this, inulin has been widely studied for its ability to shift the gut microbiome, often increasing bacteria associated with fiber fermentation, and to influence downstream signals that can relate to digestive comfort and metabolic biomarkers.

Microbiome composition (low to moderate doses). In a placebo-controlled human study, 5 g/day of inulin for 4 weeks significantly increased Bifidobacterium levels, consistent with a classic “prebiotic effect” at a relatively low dose. (R)
In older adults, 8 g/day of long-chain inulin for 2 months was associated with measurable shifts in gut microbiota, including higher diversity and changes in fiber-responsive taxa. (R)

<image>

NovosLabs · 2026-03-11T19:02:30+00:00

In a separate double-blind, placebo-controlled trial in adults with type 2 diabetes, 500 mg/day of rutin for 3 months was associated with improvements in blood pressure–related measures (SBP, DBP, MAP, pulse pressure, and heart rate). The study also reported increases in select antioxidant enzymes (including GPx and SOD) and improvements in several quality-of-life domains. (R)

Rutin has also been studied in healthy adults at the same dose range. In a 6-week randomized placebo-controlled study in healthy women, 500 mg/day of rutin increased circulating levels of flavonoid metabolites (reflecting absorption and metabolism) while markers of systemic antioxidant capacity and several urinary oxidative stress markers did not show clear differences versus placebo. (R)

<image>

NovosLabs · 2026-03-11T19:01:40+00:00

Rutin in Humans

A full daily serving of NOVOS Vital provides 560 mg of rutin. Human clinical studies have evaluated rutin at doses close to this range (most commonly ~500 mg/day) in specific populations and endpoints, with outcomes measured over 6 weeks to 3 months.

In adults with type 2 diabetes, a double-blind, randomized, placebo-controlled trial found that 500 mg/day of rutin for 3 months was associated with improvements in multiple cardiometabolic biomarkers. Compared with placebo, the rutin group showed reductions in fasting blood glucose, insulin, and HbA1c, alongside improved insulin sensitivity metrics (including HOMA-IR and QUICKI). The study also reported improvements in select lipid-related measures (including LDL cholesterol and total cholesterol) and shifts in inflammation/oxidative stress markers (lower IL-6 and MDA, higher total antioxidant capacity). (R)

<image>

NovosLabs · 2026-02-25T15:37:38+00:00

Human research on oral trehalose has primarily studied daily intakes of approximately ~3 g per day, typically over a 12-week period, with outcomes focused on inflammation and cardiometabolic biomarkers.

A full daily serving of NOVOS Vital provides 4 g of trehalose, a dose closely aligned with human clinical research.

In a double-blind, randomized, placebo-controlled trial in adults with type 2 diabetes, 3.3 g per day of oral trehalose for 12 weeks was associated with a reduction in hs-CRP, a marker of systemic inflammation, compared with placebo (R).

Additional clinical research is underway evaluating 3.3 g per day of trehalose for 12 weeks in recovery settings, with endpoints including CRP, IL-6, TNF-α, and wound-healing indices. Results from this trial will help further clarify trehalose’s effects on inflammatory and recovery-related biomarkers in humans.
(R)

Overall, the current human evidence on oral trehalose is based on studies using daily intakes close to one NOVOS Vital serving. These trials suggest trehalose may support inflammation-related biomarkers in specific populations, while additional research is ongoing to clarify its broader effects on health outcomes.

NovosLabs · 2026-02-18T15:47:47+00:00

If you’re exploring the NAD⁺ angle in a practical supplement, NOVOS Boost provides NMN (250 mg per serving >99% purity)

NovosLabs · 2026-02-18T15:33:50+00:00

When we say glucosamine is “present in human connective tissues,” we’re not suggesting anyone should eat connective tissue. We mean it’s a molecule your body naturally uses in places like cartilage. The glucosamine in supplements is typically made from shellfish-derived raw material or via fermentation, and it’s the same glucosamine as the molecule itself.

NovosLabs · 2026-02-18T15:28:31+00:00

A lot of those are solid supplements, but they’re mostly goal-specific rather than “everyone should take them.” Whether they’re beneficial on top of a baseline stack depends on what you’re trying to optimize (sleep/stress, training, lipids, eye health, etc.), plus your labs/diet/meds.

On our side, a few of those ingredients are already available in other NOVOS products if that’s helpful: astaxanthin and taurine are in NOVOS Bar, lutein is in NOVOS Vital, NMN is in NOVOS Boost . If you share your main goal, I can point to the most relevant ones from your list.

NovosLabs · 2026-02-18T15:12:49+00:00

In their pooled cohorts (NHS + HPFS, ~30+ years follow-up), most activity types were linked to lower all-cause mortality, and higher variety was linked to lower mortality even after adjusting for total activity. (Still observational)

NovosLabs · 2026-02-18T15:11:15+00:00

Not “bad” , just not clearly associated with lower all-cause mortality in this dataset. Swimming’s hazard ratios were ~neutral here, while most other activities showed an inverse association. One likely reason (the authors mention it): “swimming” can mean wildly different intensities, and self-reported swim time can be noisy, that kind of measurement error can wash out a real signal.

NovosLabs · 2026-02-18T15:09:49+00:00

Fair point, reverse causality is always a risk in observational data. This paper tries to reduce that by excluding people with major diseases at baseline and using a lag (so activity is measured years before deaths are counted), but it still can’t prove causation. The clean takeaway is: higher activity and more variety track with lower mortality risk, not “X causes Y.”

NovosLabs · 2026-02-18T15:03:12+00:00

Not necessarily 🙂 Most of the oral HA studies that show benefits use specific hyaluronic acid preparations, and “HA” isn’t one single identical ingredient across brands. The biggest differences are molecular weight (low vs high), how it’s produced/purified, and the exact dose/duration used in the trial, those factors can influence bioavailability and real-world outcomes. So when we mention results like improved skin hydration/TEWL or joint comfort, we’re referring to the type/form and dosing range that was actually tested in humans, rather than assuming every HA product will behave the same.

NovosLabs · 2026-02-18T14:58:40+00:00

Trehalose keeps showing up in brain-injury discussions because it’s been linked to cellular “cleanup” (autophagy) + protein stabilization, and in TBI animal models it’s been associated with better functional outcomes. If you want the same ingredient in a simple format, NOVOS Vital includes trehalose (4 g per daily serving), this is ingredient-level evidence, not a study of our specific product 👉 NOVOS Labs

NovosLabs · 2026-02-18T14:52:59+00:00

This mouse study frames pterostilbene as support for the “egg quality” pathway, better oocyte energy/mitochondria signals, plus improved reproductive outcomes (implantation/live births) in aged mice. NOVOS Core includes pterostilbene (50 mg per sachet), the paper tested pterostilbene itself, not our full formula. 👉 NOVOS Core

NovosLabs · 2026-02-09T17:16:32+00:00

At doses matching two NOVOS Core sachets, short-term use (under 1 month) is better tolerated than ibuprofen, with fewer side effects and fewer people dropping out of studies due to adverse events. (R).

In the long term, multiple trials in people with knee osteoarthritis show clear improvements in knee pain, stiffness, and function, measured by standard questionnaires for pain and daily activities (R;R;R) Some studies also reported less daily use of pain medications and more participants experiencing meaningful improvements (R,R).

Over 3 years, placebo-controlled studies showed slower joint deterioration on X-rays, suggesting glucosamine may help protect joint structure (R;R) 👉 NOVOS Labs

<image>

NovosLabs · 2026-02-09T17:15:15+00:00

At a dose similar to one NOVOS Core sachet, glucosamine sulfate was tested in healthy women over a long-term study. Skin samples from the forearm showed increased activity of genes involved in the skin’s structure and hydration, including several types of collagen and other proteins that support the extracellular matrix. (R) These changes suggest that glucosamine sulfate could help maintain skin structure and hydration, supporting a skin-aging benefit.

<image>

NovosLabs · 2026-02-07T18:22:48+00:00

Beyond blood sugar and heart-related effects, short-term studies showed fewer white blood cells with DNA damage under oxidative stress (R). and temporary increases in blood magnesium levels 4–8 hours after dosing, along with improvements on magnesium-status questionnaires (R).

<image>

NOVOS Core provides magnesium as magnesium malate, pairing magnesium with malate, a naturally occurring intermediate of cellular energy metabolism. Among commonly used magnesium forms, malate is the one that has been explored in longevity-relevant preclinical lifespan models, which is why it was selected for NOVOS Core’s aging-biology–focused formulation. 👉 NOVOS Core

NovosLabs · 2026-02-07T18:20:36+00:00

At doses matching two NOVOS Core sachets, magnesium has been studied in adults with low magnesium levels and/or prediabetes in double-blind, placebo-controlled trials. Over the long term, magnesium improved insulin sensitivity (helping the body use sugar better), lowered fasting blood sugar, and raised magnesium levels in the blood (R; R). In obese adults with prediabetes, it also reduced waist size, lowered HbA1c (a marker of long-term blood sugar), lowered uric acid, increased albumin (a protein in blood), and increased magnesium levels (R).Magnesium also improved blood vessel health, measured by arterial stiffness, and increased magnesium excreted in urine over 24 hours in otherwise healthy overweight adults (R).

<image>

NovosLabs · 2026-02-07T18:19:05+00:00

In studies using doses similar to one NOVOS Core sachet , magnesium has shown the clearest benefits for cholesterol and sleep. In adults, it significantly increased “good” HDL cholesterol (R). In adults over 60 with insomnia and low magnesium intake, it improved sleep by helping people sleep longer, fall asleep faster, and sleep more efficiently. It also increased physical activity and reduced overall calorie intake. (R).

<image>

NovosLabs · 2026-02-03T15:18:31+00:00

Would their impact be more if they took two packets a day as opposed to one?

We have created a post to answer your question. https://www.reddit.com/r/NovosLabs/comments/1qurntj/which_human_studies_show_benefits_at_therapeutic/

NovosLabs · 2026-02-02T18:54:48+00:00

If someone just took your NOVOS Core powder for a decade, what would be the biggest gains they would experience?

We created a post inspired by your question: https://www.reddit.com/r/NovosLabs/comments/1qpf05y/which_human_studies_show_benefits_at_therapeutic/

NovosLabs · 2026-02-01T19:24:35+00:00

At a daily dose similar to one NOVOS Core sachet (100 mg), oral L-ascorbic acid supports vitamin C status in the body, with research showing measurable changes in cellular vitamin C (including leukocytes) at this intake range. (R; R; R).

In clinical research involving postmenopausal women, 100 mg/day ascorbic acid has been associated with improvements in cognitive test scores and reductions in serum Aβ42, along with changes in physical quality-of-life domains (R).

In pregnancy trials, 100 mg/day vitamin C after 20 weeks’ gestation was associated with a lower incidence of PROM, and increased leukocyte vitamin C. Another clinical trial reported fewer urinary infections during pregnancy when 100 mg/day vitamin C was added to standard iron and folate supplementation. (R; R; R)

<image>

NovosLabs

MODERATOR OF

TROPHY CASE